John F. Carey - Jul 29, 2022 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
VP of Operations
Signature
By: /s/ Stephen Gordon, as attorney-in-fact
Stock symbol
TMDX
Transactions as of
Jul 29, 2022
Transactions value $
-$245,778
Form type
4
Date filed
8/1/2022, 08:40 PM
Previous filing
Jul 22, 2022
Next filing
Sep 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $27.1K +2.04K +264.72% $13.28* 2.81K Jul 29, 2022 Direct F1, F6
transaction TMDX Common Stock Options Exercise $4.33K +1.96K +69.67% $2.21* 4.77K Jul 29, 2022 Direct F1, F6
transaction TMDX Common Stock Sale -$160K -4K -83.84% $40.01 771 Jul 29, 2022 Direct F1, F2, F6
transaction TMDX Common Stock Options Exercise $6.63K +3K +389.11% $2.21* 3.77K Aug 1, 2022 Direct F1, F6
transaction TMDX Common Stock Sale -$16K -400 -10.61% $40.02 3.37K Aug 1, 2022 Direct F1, F3, F6
transaction TMDX Common Stock Sale -$91.1K -2.2K -65.26% $41.39 1.17K Aug 1, 2022 Direct F1, F4, F6
transaction TMDX Common Stock Sale -$16.7K -400 -34.16% $41.84 771 Aug 1, 2022 Direct F1, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -2.04K -5.53% $0.00 34.8K Jul 29, 2022 Common Stock 2.04K $13.28 Direct F1, F7
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -1.96K -18.24% $0.00 8.78K Jul 29, 2022 Common Stock 1.96K $2.21 Direct F1, F8
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -3K -34.15% $0.00 5.78K Aug 1, 2022 Common Stock 3K $2.21 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $40.00 to $40.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $39.60 to $40.39, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $40.78 to $41.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $41.78 to $41.95, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The amount of securities directly owned by the Reporting Person includes 392 shares of common stock acquired under the TransMedics Group, Inc. 2019 Employee Stock Purchase Plan.
F7 The option vested and will continue to vest at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 22, 2022. As of the date of this report, the option remains subject to vesting with respect to 34,042 shares.
F8 The option is fully vested.